Paraneoplastic Muscle Disease

Rheumatic Disease Clinics of North America

Volumn 37, Issue 2, 2011, Pages 185-200

  Baer, Alan N ^a  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Dermatomyositis; Eaton Lambert syndrome; Malignancy; Myasthenia gravis; Myopathy; Paraneoplastic; Polymyositis; Stiff person syndrome

Indexed keywords

ANTINEOPLASTIC AGENT; CREATINE KINASE;

ACTION POTENTIAL; ADENOCARCINOMA; ANTIBODY TITER; BLADDER CANCER; CANCER SCREENING; CANCER STAGING; CLINICAL FEATURE; DERMATOMYOSITIS; DISEASE ASSOCIATION; DISEASE COURSE; DISEASE SEVERITY; EATON LAMBERT SYNDROME; ELECTROMYOGRAPHY; HUMAN; INCLUSION BODY MYOSITIS; LUNG CANCER; MUSCLE BIOPSY; MUSCLE WEAKNESS; MYASTHENIA GRAVIS; MYOPATHY; MYOSITIS; NEUROMUSCULAR TRANSMISSION; NONHODGKIN LYMPHOMA; NUCLEAR MAGNETIC RESONANCE IMAGING; PARANEOPLASTIC MUSCLE DISEASE; PARANEOPLASTIC SYNDROME; PATHOGENESIS; POLYMYOSITIS; POPULATION RESEARCH; PRIORITY JOURNAL; REVIEW; RISK ASSESSMENT; RISK FACTOR; SENSITIVITY AND SPECIFICITY; STIFF MAN SYNDROME; STOMACH CARCINOMA; TUMOR LOCALIZATION; TUMOR RECURRENCE;

ADULT; FEMALE; HUMANS; MALE; MUSCLE WEAKNESS; MUSCULAR DISEASES; NEOPLASMS, UNKNOWN PRIMARY; NEUROMUSCULAR JUNCTION DISEASES; PARANEOPLASTIC SYNDROMES;

EID: 79953065608     PISSN: 0889857X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.rdc.2011.01.011     Document Type: Review

References (101)

1. Honnorat J., Antoine J.C. Paraneoplastic neurological syndromes. Orphanet J Rare Dis 2007, 2:22.
2. Darnell R.B., Posner J.B. Paraneoplastic syndromes involving the nervous system. N Engl J Med 2003, 349(16):1543-1554.
3. Graus F., Delattre J.Y., Antoine J.C., et al. Recommended diagnostic criteria for paraneoplastic neurological syndromes. J Neurol Neurosurg Psychiatry 2004, 75(8):1135-1140.
4. Stertz G. Polymyositis. Berl Klin Wochenschr 1916, 53:489.
5. Kankeleit H. Uber primare nichteitrige polymyositis. Dtsch Arch Klin Med 1916, 120:335-349. [in German].
6. Buchbinder R., Hill C.L. Malignancy in patients with inflammatory myopathy. Curr Rheumatol Rep 2002, 4(5):415-426.
7. Bohan A., Peter J.B. Polymyositis and dermatomyositis (first of two parts). N Engl J Med 1975, 292(7):344-347.
8. Miller F.W., Rider L.G., Plotz P.H., et al. Diagnostic criteria for polymyositis and dermatomyositis. Lancet 2003, 362(9397):1762-1763. [author reply: 1763].
9. Hoffman G.S., Franck W.A., Raddatz D.A., et al. Presentation, treatment, and prognosis of idiopathic inflammatory muscle disease in a rural hospital. Am J Med 1983, 75(3):433-438.
10. Baron M., Small P. Polymyositis/dermatomyositis: clinical features and outcome in 22 patients. J Rheumatol 1985, 12(2):283-286.
11. Koh E.T., Seow A., Ong B., et al. Adult onset polymyositis/dermatomyositis: clinical and laboratory features and treatment response in 75 patients. Ann Rheum Dis 1993, 52(12):857-861.
12. Andras C., Ponyi A., Constantin T., et al. Dermatomyositis and polymyositis associated with malignancy: a 21-year retrospective study. J Rheumatol 2008, 35(3):438-444.
13. Wakata N., Kurihara T., Saito E., et al. Polymyositis and dermatomyositis associated with malignancy: a 30-year retrospective study. Int J Dermatol 2002, 41(11):729-734.
14. Callen J.P., Hyla J.F., Bole G.G., et al. The relationship of dermatomyositis and polymyositis to internal malignancy. Arch Dermatol 1980, 116(3):295-298.
15. Maoz C.R., Langevitz P., Livneh A., et al. High incidence of malignancies in patients with dermatomyositis and polymyositis: an 11-year analysis. Semin Arthritis Rheum 1998, 27(5):319-324.
16. Bohan A., Peter J.B., Bowman R.L., et al. Computer-assisted analysis of 153 patients with polymyositis and dermatomyositis. Medicine (Baltimore) 1977, 56(4):255-286.
17. Benbassat J., Gefel D., Larholt K., et al. Prognostic factors in polymyositis/dermatomyositis. A computer-assisted analysis of ninety-two cases. Arthritis Rheum 1985, 28(3):249-255.
18. Cherin P., Piette J.C., Herson S., et al. Dermatomyositis and ovarian cancer: a report of 7 cases and literature review. J Rheumatol 1993, 20(11):1897-1899.
19. Chen Y.J., Wu C.Y., Shen J.L. Predicting factors of malignancy in dermatomyositis and polymyositis: a case-control study. Br J Dermatol 2001, 144(4):825-831.
20. Manchul L.A., Jin A., Pritchard K.I., et al. The frequency of malignant neoplasms in patients with polymyositis-dermatomyositis. A controlled study. Arch Intern Med 1985, 145(10):1835-1839.
21. Lakhanpal S., Bunch T.W., Ilstrup D.M., et al. Polymyositis-dermatomyositis and malignant lesions: does an association exist?. Mayo Clin Proc 1986, 61(8):645-653.
22. Tymms K.E., Webb J. Dermatopolymyositis and other connective tissue diseases: a review of 105 cases. J Rheumatol 1985, 12(6):1140-1148.
23. Henriksson K.G., Sandstedt P. Polymyositis-treatment and prognosis. A study of 107 patients. Acta Neurol Scand 1982, 65(4):280-300.
24. Holden D.J., Brownell A.K., Fritzler M.J. Clinical and serologic features of patients with polymyositis or dermatomyositis. Can Med Assoc J 1985, 132(6):649-653.
25. Ponge A., Mussini J.M., Ponge T., et al. Paraneoplastic dermatopolymyositis. Rev Med Interne 1987, 8(3):251-256.
26. Lee S.W., Jung S.Y., Park M.C., et al. Malignancies in Korean patients with inflammatory myopathy. Yonsei Med J 2006, 47(4):519-523.
27. Sparsa A., Liozon E., Herrmann F., et al. Routine vs extensive malignancy search for adult dermatomyositis and polymyositis: a study of 40 patients. Arch Dermatol 2002, 138(7):885-890.
28. Hochberg M.C., Feldman D., Stevens M.B. Adult onset polymyositis/dermatomyositis: an analysis of clinical and laboratory features and survival in 76 patients with a review of the literature. Semin Arthritis Rheum 1986, 15(3):168-178.
29. Antiochos B.B., Brown L.A., Wortmann R.L., et al. Malignancy is associated with dermatomyositis, but not polymyositis in northern New England. Arthritis Rheum 2008, 58(Suppl 9):S230-S231.
30. Dourmishev L.A. Dermatomyositis associated with malignancy. 12 case reports. Adv Exp Med Biol 1999, 455:193-199.
31. Gallais V., Crickx B., Belaich S. Prognostic factors and predictive signs of malignancy in adult dermatomyositis. Ann Dermatol Venereol 1996, 123(11):722-726.
32. Basset-Seguin N., Roujeau J.C., Gherardi R., et al. Prognostic factors and predictive signs of malignancy in adult dermatomyositis. A study of 32 cases. Arch Dermatol 1990, 126(5):633-637.
33. Cox N.H., Lawrence C.M., Langtry J.A., et al. Disease associations and an evaluation of screening investigations for malignancy. Arch Dermatol 1990, 126(1):61-65.
34. Goh C.L., Rajan V.S. Dermatomyositis in a skin clinic. Ann Acad Med Singapore 1983, 12(1):6-12.
35. Leow Y.H., Goh C.L. Malignancy in adult dermatomyositis. Int J Dermatol 1997, 36(12):904-907.
36. Bonnetblanc J.M., Bernard P., Fayol J. Dermatomyositis and malignancy. A multicenter cooperative study. Dermatologica 1990, 180(4):212-216.
37. Ang P., Sugeng M.W., Chua S.H. Classical and amyopathic dermatomyositis seen at the National Skin Centre of Singapore: a 3-year retrospective review of their clinical characteristics and association with malignancy. Ann Acad Med Singapore 2000, 29(2):219-223.
38. Selvaag E., Thune P., Austad J. Dermatomyositis and cancer. A retrospective study. Tidsskr Nor Laegeforen 1994, 114(20):2378-2380.
39. Mebazaa A., Boussen H., Nouira R., et al. Dermatomyositis and malignancy in Tunisia: a multicenter national retrospective study of 20 cases. J Am Acad Dermatol 2003, 48(4):530-534.
40. Chan H.L. Dermatomyositis and cancer in Singapore. Int J Dermatol 1985, 24(7):447-450.
41. Vesterager L., Worm A.M., Thomsen K. Dermatomyositis and malignancy. Clin Exp Dermatol 1980, 5(1):31-35.
42. Ponyi A., Constantin T., Garami M., et al. Cancer-associated myositis: clinical features and prognostic signs. Ann N Y Acad Sci 2005, 1051:64-71.
43. Rose C., Hatron P.Y., Brouillard M., et al. Predictive signs of cancers in dermatomyositis. Study of 29 cases. Rev Med Interne 1994, 15(1):19-24.
44. Dawkins M.A., Jorizzo J.L., Walker F.O., et al. Dermatomyositis: a dermatology-based case series. J Am Acad Dermatol 1998, 38(3):397-404.
45. Fardet L., Dupuy A., Gain M., et al. Factors associated with underlying malignancy in a retrospective cohort of 121 patients with dermatomyositis. Medicine (Baltimore) 2009, 88(2):91-97.
46. Prohic A., Kasumagic-Halilovic E., Simic D., et al. Clinical and biological factors predictive of malignancy in dermatomyositis. J Eur Acad Dermatol Venereol 2009, 23(5):591-592.
47. Zhang W., Jiang S.P., Huang L. Dermatomyositis and malignancy: a retrospective study of 115 cases. Eur Rev Med Pharmacol Sci 2009, 13(2):77-80.
48. Masi A.T., Hochberg M.C. Temporal association of polymyositis-dermatomyositis with malignancy: methodologic and clinical considerations. Mt Sinai J Med 1988, 55(6):471-478.
49. Buchbinder R., Forbes A., Hall S., et al. Incidence of malignant disease in biopsy-proven inflammatory myopathy. A population-based cohort study. Ann Intern Med 2001, 134(12):1087-1095.
50. Airio A., Pukkala E., Isomaki H. Elevated cancer incidence in patients with dermatomyositis: a population based study. J Rheumatol 1995, 22(7):1300-1303.
51. Stockton D., Doherty V.R., Brewster D.H. Risk of cancer in patients with dermatomyositis or polymyositis, and follow-up implications: a Scottish population-based cohort study. Br J Cancer 2001, 85(1):41-45.
52. Chow W.H., Gridley G., Mellemkjaer L., et al. Cancer risk following polymyositis and dermatomyositis: a nationwide cohort study in Denmark. Cancer Causes Control 1995, 6(1):9-13.
53. Sigurgeirsson B., Lindelof B., Edhag O., et al. Risk of cancer in patients with dermatomyositis or polymyositis. A population-based study. N Engl J Med 1992, 326(6):363-367.
54. Hill C.L., Zhang Y., Sigurgeirsson B., et al. Frequency of specific cancer types in dermatomyositis and polymyositis: a population-based study. Lancet 2001, 357(9250):96-100.
55. Peng J.C., Sheen T.S., Hsu M.M. Nasopharyngeal carcinoma with dermatomyositis. Analysis of 12 cases. Arch Otolaryngol Head Neck Surg 1995, 121(11):1298-1301.
56. Hatada T., Aoki I., Ikeda H., et al. Dermatomyositis and malignancy: case report and review of the Japanese literature. Tumori 1996, 82(3):273-275.
57. Davis M.D., Ahmed I. Ovarian malignancy in patients with dermatomyositis and polymyositis: a retrospective analysis of fourteen cases. J Am Acad Dermatol 1997, 37(5 Pt 1):730-733.
58. Mordel N., Margalioth E.J., Harats N., et al. Concurrence of ovarian cancer and dermatomyositis. A report of two cases and literature review. J Reprod Med 1988, 33(7):649-655.
59. Fujita J., Tokuda M., Bandoh S., et al. Primary lung cancer associated with polymyositis/dermatomyositis, with a review of the literature. Rheumatol Int 2001, 20(2):81-84.
60. Masuda H., Urushibara M., Kihara K. Successful treatment of dermatomyositis associated with adenocarcinoma of the prostate after radical prostatectomy. J Urol 2003, 169(3):1084.
61. Tallai B., Flasko T., Gyorgy T., et al. Prostate cancer underlying acute, definitive dermatomyositis: successful treatment with radical perineal prostatectomy. Clin Rheumatol 2006, 25(1):119-120.
62. Yoshinaga A., Hayashi T., Ishii N., et al. Successful cure of dermatomyositis after treatment of nonseminomatous testicular cancer. Int J Urol 2005, 12(6):593-595.
63. Solomon S.D., Maurer K.H. Association of dermatomyositis and dysgerminoma in a 16-year-old patient. Arthritis Rheum 1983, 26(4):572-573.
64. Callen J.P. Dermatomyositis and female malignancy. J Surg Oncol 1986, 32(2):121-124.
65. Barnes B.E., Mawr B. Dermatomyositis and malignancy. A review of the literature. Ann Intern Med 1976, 84(1):68-76.
66. Whitmore S.E., Rosenshein N.B., Provost T.T. Ovarian cancer in patients with dermatomyositis. Medicine (Baltimore) 1994, 73(3):153-160.
67. Pautas E., Cherin P., Piette J.C., et al. Features of polymyositis and dermatomyositis in the elderly: a case-control study. Clin Exp Rheumatol 2000, 18(2):241-244.
68. Marie I., Hatron P.Y., Levesque H., et al. Influence of age on characteristics of polymyositis and dermatomyositis in adults. Medicine (Baltimore) 1999, 78(3):139-147.
69. Mahe E., Descamps V., Burnouf M., et al. A helpful clinical sign predictive of cancer in adult dermatomyositis: cutaneous necrosis. Arch Dermatol 2003, 139(4):539.
70. Mautner G.H., Grossman M.E., Silvers D.N., et al. Epidermal necrosis as a predictive sign of malignancy in adult dermatomyositis. Cutis 1998, 61(4):190-194.
71. Hunger R.E., Durr C., Brand C.U. Cutaneous leukocytoclastic vasculitis in dermatomyositis suggests malignancy. Dermatology 2001, 202(2):123-126.
72. Amerio P., Girardelli C.R., Proietto G., et al. Usefulness of erythrocyte sedimentation rate as tumor marker in cancer associated dermatomyositis. Eur J Dermatol 2002, 12(2):165-169.
73. Amoura Z., Duhaut P., Huong D.L., et al. Tumor antigen markers for the detection of solid cancers in inflammatory myopathies. Cancer Epidemiol Biomarkers Prev 2005, 14(5):1279-1282.
74. O'Gradaigh D., Merry P. Tumour markers in dermatomyositis: useful or useless?. Br J Rheumatol 1998, 37(8):914.
75. Whitmore S.E., Anhalt G.J., Provost T.T., et al. Serum CA-125 screening for ovarian cancer in patients with dermatomyositis. Gynecol Oncol 1997, 65(2):241-244.
76. Winkelmann R.K. The cutaneous diagnosis of dermatomyositis, lupus erythematosus, and scleroderma. N Y State J Med 1963, 63:3080-3086.
77. Whitmore S.E., Watson R., Rosenshein N.B., et al. Dermatomyositis sine myositis: association with malignancy. J Rheumatol 1996, 23(1):101-105.
78. Fung W.K., Chan H.L., Lam W.M. Amyopathic dermatomyositis in Hong Kong-association with nasopharyngeal carcinoma. Int J Dermatol 1998, 37(9):659-663.
79. Chinoy H., Fertig N., Oddis C.V., et al. The diagnostic utility of myositis autoantibody testing for predicting the risk of cancer-associated myositis. Ann Rheum Dis 2007, 66(10):1345-1349.
80. Hengstman G.J., Brouwer R., Egberts W.T., et al. Clinical and serological characteristics of 125 Dutch myositis patients. Myositis specific autoantibodies aid in the differential diagnosis of the idiopathic inflammatory myopathies. J Neurol 2002, 249(1):69-75.
81. Selva-O'Callaghan A., Labrador-Horrillo M., Solans-Laque R., et al. Myositis-specific and myositis-associated antibodies in a series of eighty-eight Mediterranean patients with idiopathic inflammatory myopathy. Arthritis Rheum 2006, 55(5):791-798.
82. O'Hanlon T.P., Carrick D.M., Targoff I.N., et al. Immunogenetic risk and protective factors for the idiopathic inflammatory myopathies: distinct HLA-A, -B, -Cw, -DRB1, and -DQA1 allelic profiles distinguish European American patients with different myositis autoantibodies. Medicine (Baltimore) 2006, 85(2):111-127.
83. Legault D., McDermott J., Crous-Tsanaclis A.M., et al. Cancer-associated myositis in the presence of anti-Jo1 autoantibodies and the antisynthetase syndrome. J Rheumatol 2008, 35(1):169-171.
84. Kaji K., Fujimoto M., Hasegawa M., et al. Identification of a novel autoantibody reactive with 155 and 140 kDa nuclear proteins in patients with dermatomyositis: an association with malignancy. Rheumatology (Oxford) 2007, 46(1):25-28.
85. Fudman E.J., Schnitzer T.J. Dermatomyositis without creatine kinase elevation. A poor prognostic sign. Am J Med 1986, 80(2):329-332.
86. Callen J.P. The value of malignancy evaluation in patients with dermatomyositis. J Am Acad Dermatol 1982, 6(2):253-259.
87. Pautas E., Cherin P. Investigation of polymyositis-dermatomyositis in older people should include rectal examination. J Am Geriatr Soc 1998, 46(12):1584.
88. Callen J.P. When and how should the patient with dermatomyositis or amyopathic dermatomyositis be assessed for possible cancer?. Arch Dermatol 2002, 138(7):969-971.
89. Schulman P., Kerr L.D., Spiera H. A reexamination of the relationship between myositis and malignancy. J Rheumatol 1991, 18(11):1689-1692.
90. Levine S.M. Cancer and myositis: new insights into an old association. Curr Opin Rheumatol 2006, 18(6):620-624.
91. Casciola-Rosen L., Nagaraju K., Plotz P., et al. Enhanced autoantigen expression in regenerating muscle cells in idiopathic inflammatory myopathy. J Exp Med 2005, 201(4):591-601.
92. Bronner I.M., Hoogendijk J.E., Wintzen A.R., et al. Necrotising myopathy, an unusual presentation of a steroid-responsive myopathy. J Neurol 2003, 250(4):480-485.
93. Levin M.I., Mozaffar T., Al-Lozi M.T., et al. Paraneoplastic necrotizing myopathy: clinical and pathological features. Neurology 1998, 50(3):764-767.
94. Emslie-Smith A.M., Engel A.G. Necrotizing myopathy with pipestem capillaries, microvascular deposition of the complement membrane attack complex (MAC), and minimal cellular infiltration. Neurology 1991, 41(6):936-939.
95. Silvestre J., Santos L., Batalha V., et al. Paraneoplastic necrotizing myopathy in a woman with breast cancer: a case report. J Med Case Reports 2009, 3:95.
96. Hengstman G.J., ter Laak H.J., Vree Egberts W.T., et al. Anti-signal recognition particle autoantibodies: marker of a necrotising myopathy. Ann Rheum Dis 2006, 65(12):1635-1638.
97. Christopher-Stine L., Casciola-Rosen L.A., Hong G., et al. A novel autoantibody recognizing 200-kd and 100-kd proteins is associated with an immune-mediated necrotizing myopathy. Arthritis Rheum 2010, 62(9):2757-2766.
98. Sarui H., Maruyama T., Ito I., et al. Necrotising myositis in Behcet's disease: characteristic features on magnetic resonance imaging and a review of the literature. Ann Rheum Dis 2002, 61(8):751-752.
99. Sampson J.B., Smith S.M., Smith A.G., et al. Paraneoplastic myopathy: response to intravenous immunoglobulin. Neuromuscul Disord 2007, 17(5):404-408.
100. Levin N., Abramsky O., Lossos A., et al. Extrathymic malignancies in patients with myasthenia gravis. J Neurol Sci 2005, 237(1/2):39-43.
101. Romi F., Skeie G.O., Aarli J.A., et al. Muscle autoantibodies in subgroups of myasthenia gravis patients. J Neurol 2000, 247(5):369-375.